Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Hemangioma Clinical Trials

A listing of Hemangioma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (14) clinical trials

Nadolol Versus Propranolol in Children With Infantile Hemangiomas

The study objective is to compare the efficacy and safety of oral propranolol in comparison with oral nadolol in patients with IH. Patients will be randomly assigned to either propranolol or dose equivalent nadolol. The duration of the study will be 24 weeks, however, patient will be monitored for up ...

Phase

A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain

This pilot study aims to evaluate the efficacy and safety of hemoporfin photodynamic therapy (PDT) with different light doses for port-wine stain (PWS in 7-14 years old children. The population pharmacokinetics of hemoporfin in children will be investigated as well.

Phase

Novel Treatment for Port Wine Stain Birthmarks

Pulsed dye laser is currently the standard of care treatment for Port wine stains. Researchers at University of California Irvine at Beckman Laser Institute Medical Clinic can use Photodynamic therapy, another treatment option for Port wine stains. Photodynamic therapy involves light activation of a photosensitizer (a drug that is responsive ...

Phase

CyberKnife Based Hypofractionated Radiotherapy for Vertebral Hemangiomas

Hemangiomas are frequent vertebral lesions (12% of the whole human population) but only 1% displays any clinical symptoms . The most common symptom is local pain, usually non responding for non-steroid anti-inflammatory drugs. Radiation therapy usually does not result calcification or the tumor regression, but significantly reduces the pain intensity ...

Phase

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn

Hemangiomas affect 5-10% of all children born in the United States and up to 20% of premature infants, with a higher incidence in girls. Most infantile hemangiomas (IHs) appear within a few weeks of birth, grow rapidly for months to years and eventually involute. "Benign neglect" (no treatment) is therefore ...

Phase N/A

Topical Timolol for Infantile Hemangioma in Early Proliferative Phase

A multicentric, randomized, double-blind, placebo-controlled, phase II clinical trial to evaluate the efficacy and safety of 0.5% timolol maleate solution for the early treatment of infantile hemangioma. Patients with less of 60 days of life with focal or segmental hemangiomas, superficial, mixed or abortive will be treated with topical timolol ...

Phase

Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB

The labeling of albumin has advantages as drawing blood is unnecessary and the operator labeling is not exposed to potentially infectious material. Evans blue (EB) dye has high affinity for serum albumin, The final obtained products NEB (a NOTA conjugate of a truncated form of Evans blue for in vivo ...

Phase

Bevacizumab and Radiation Therapy for Sarcomas

- The dose of bevacizumab and radiation therapy will be the same for all participants throughout the study. - Bevacizumab will be given as an intravenous infusion every 2 weeks for a total of 4 doses. - Radiation therapy will begin 2 weeks after the first bevacizumab infusion and will ...

Phase

Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain

This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in the Chinese population, such as unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine ...

Phase

Efficacy Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)

Primary: Describe the efficacy of 0.25% and 0.5% topical timolol maleate GFS as assessed through IH changes in volume. Secondary: Describe the safety and PK of topical timolol maleate GFS for treatment of IH.

Phase